However, DGAT1 null mice exhibit skin aberrations, presumably due to depletion of essential lipids within the skin [3], and thus the DGAT1 inhibitor could induce skin aberrations when systemically administered for the treatment of obesity and diabetes. Here, DGAT1 is linked to obesity due to melanocortin 4 receptor deficiency.